Breast Lift in Hungary
Breast Lift in Hungary section, includes general infrmation about Breast Lift Procedure, Breast Lift Hungary Local News, Breast Lift Hungary Surgeon Locator and other Breast Lift related material.
Breast Lift Procedure
A mastopexy or breast lift is a surgical procedure performed to reshape the breast and return it to a more youthful position. Drooping of the breast may occur after pregnancy as well as aging. Frequently a breast implant may be used in conjunction with a breast lift in order to achieve better results. Depending on the amount of breast lifting that needs to be accomplished, different techniques may be used that involve different incisions. Generally, the more lifting that is required, the larger the incision (and therefore the scar).
Other Breast Lift Procedures
All Breast Procedures
Breast Lift Hungary (current)
Hungary Breast Reduction
Hungary Breast Implants
Hungary Implant Removal
Hungary Armpit Incision
More Hungary info...
Plastic Surgery News...
- A survey published by national charity Action for Blind People has revealed that 1.2 million blind and partially sighted people in the UK have experienced physical and/or verbal abuse: - In one day nearly 20,000 (4%) blind and partially sighted people were physically abused, compared to less than 1% of sighted people.
- According to an updated analysis of the TAX 327 study, treatment of advanced prostate cancer with 3-weekly docetaxel in addition to prednisone resulted in statistically significantly longer survival times compared to treatment with mitoxantrone in combination with prednisone.
The TAX 327 study had compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The initial analysis at Aug 2003 when 557 deaths had already occurred, had shown statistically significant better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with MP.
The updated analysis, performed in March 2007 showed the following results:
• An additional 310 deaths had occurred
• The survival benefit of D3P compared with MP has persisted with extended follow-up (P = 0.004).
• Median survival time was 19.2 months (95% CI, 17.5 to 21.3 months; p=0.004 compared to MP) in the D3P arm, 17.8 months (95% CI, 16.2 to 19.2 months; p=0.086 compared to MP) in the D1P arm, and 16.3 months (95% CI, 14.3 to 17.9 months) in the MP arm.
• More patients survived >/= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%); detailed statistical data to show significance not presented
• Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.